Aniruddh Kapoor, MD
Pulmonary Disease · Milwaukee, WINPI 1982098042
Payments from drug & device makers
What this record shows
This record is dominated by education: $16,500 of the $19,641 with a category attached, or 84.0%. Intuitive Surgical accounts for 95.0% of it on its own, with 6 other manufacturers making up the rest. Among pulmonary disease clinicians in WI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 29 payments — averaging $677.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$19K
- Galvanize Therapeutics, Inc$327
- Bard Peripheral Vascular, Inc.$191
- Pulmonx Corporation$140
- Boehringer Ingelheim$122
- GSK$122
- plus $79 from 1 others
What the payments were for
- Travel & lodging$8834%
- Food & beverage$2,25811%
- Education$16,50084%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 20 | $18,659 |
| Galvanize Therapeutics, Inc | 3 | $327 |
| Bard Peripheral Vascular, Inc. | 2 | $191 |
| Pulmonx Corporation | 1 | $140 |
| Boehringer Ingelheim | 1 | $122 |
| GSK | 1 | $122 |
| La Jolla Pharmaceutical Company | 1 | $79 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$15,195
- ION$3,000
- ALIYA SYSTEM$234
- BARD MARQUEE$155
- CHARTIS CATHETER$140
- ZEPHYR DELIVERY CATHETER$140
- ZEPHYR ENDOBRONCHIAL VALVE$140
- PULMONX CHARTIS TABLET CONSOLE$140
- NUCALA$122
How this compares
$19,641 in reported general payments places this provider in the 90th percentile of 247 pulmonary disease providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 408 | $314,261 |
| OfevNintedanib Esylate | 14 | $189,441 |
| Dupixent PenDupilumab | 27 | $105,384 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 119 | $101,651 |
| Breo ElliptaFluticasone/Vilanterol | 118 | $55,446 |
| Advair HfaFluticasone Propion/Salmeterol | 103 | $47,155 |
| Spiriva HandihalerTiotropium Bromide | 54 | $46,397 |
| SymbicortBudesonide/Formoterol Fumarate | 123 | $30,372 |
| Spiriva RespimatTiotropium Bromide | 36 | $24,884 |
| Incruse ElliptaUmeclidinium Bromide | 61 | $22,984 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 79 | $20,926 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 132 | $19,239 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 24 | $13,752 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 15 | $12,411 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 444 | $11,189 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta, Arnuity Ellipta | $122 | $413,247633 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $122 | $226,73665 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 247 pulmonary disease providers in Wisconsin.
Other pulmonary disease in Milwaukee
- Jonathan KurmanMilwaukee$803K
- Mouhammed RihawiMilwaukee$713K
- Kurt HuMilwaukee$55K
- Julie BillerMilwaukee$52K
- Mark BarashMilwaukee$52K
- Rahul NanchalMilwaukee$42K
- Steven LehMilwaukee$40K
- Ali MusaniMilwaukee$38K
- Michael KatzoffMilwaukee$37K
- Uzair GhoriMilwaukee$32K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.